Remibrutinib as a Therapeutic Option for Solar Urticaria
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares +3 more
wiley +1 more source
Peripheral and central nervous system toxicities of Bruton tyrosine kinase Inhibitors: a real-world pharmacovigilance study. [PDF]
Zhang J.
europepmc +1 more source
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. [PDF]
Castillo JJ +4 more
europepmc +1 more source
Respiratory adverse-event signals of four Bruton tyrosine kinase inhibitors: cross-database replication and temporal characterization in FAERS and JADER. [PDF]
Zheng Z, Zhao F, Zhao Z, Jin P.
europepmc +1 more source
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. [PDF]
Chiu CY +8 more
europepmc +1 more source
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. [PDF]
Ermann DA +12 more
europepmc +1 more source
Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors (BTKi): A Retrospective Study From a Tertiary Healthcare Center in North India. [PDF]
Shukla A +7 more
europepmc +1 more source
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]
Caserta S +10 more
europepmc +1 more source
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma. [PDF]
Phillips T +7 more
europepmc +1 more source
Third-Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance (MGTS). [PDF]
Man L +4 more
europepmc +1 more source

